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OBJECTIVES We sought to test whether the differences in activity of the renin-angiotensin and sympathetic
nervous systems at rest or during exercise can explain the differing cardiovascular properties
and outcomes of lean and obese hypertensive patients.
BACKGROUND Although lean hypertensive patients have fewer metabolic abnormalities than obese hyper-
tensive patients, paradoxically they appear to have a poorer cardiovascular prognosis.
METHODS To evaluate the heightened risks in lean hypertensive patients, this study compared metabolic,
neuroendocrine and cardiovascular characteristics at rest and during a standardized treadmill
protocol in obese (body mass index [BMI] 5 32.5 6 0.3 kg/m2, n 5 55) and lean (BMI 5
24.3 6 0.2 kg/m2, n 5 66) hypertensive patients. Normotensive obese (n 5 21) and lean (n 5
55) volunteers served as control subjects.
RESULTS Compared with the lean normotensive subjects, the lean and obese hypertensive patients had
greater left ventricular mass index (LVMI) values, but on multivariate analysis, LVMI
correlated with plasma renin activity (p , 0.001) and plasma norepinephrine (PNE) (p ,
0.01) in the lean but not the obese hypertensive patients. Arterial compliance (stroke
volume/pulse pressure ratio) was reduced in the lean hypertensive patients, in whom it
correlated (p 5 0.033) with PNE. The PNE rose less (22%) in the obese than in the lean
(55%) hypertensive patients in response to standing (p , 0.05). Likewise, during treadmill
exercise, there were lesser increases in renin (65% vs. 145%, p , 0.01) and epinephrine (200%
vs. 500%, p , 0.05) in the obese hypertensive patients. These changes were also less in obese
patients than in lean control subjects, indicating attenuated neurohormonal responses to stress
in obesity.
CONCLUSIONS Compared with obese hypertensive patients, cardiovascular properties in lean hypertensive
patients are more dependent on catecholamines and the renin system. The different
neuroendocrine responses to dynamic stimuli in lean and obese patients also might help to
explain the disparity in their cardiovascular outcomes. (J Am Coll Cardiol 2001;37:169–74)
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Both hypertension and obesity are risk factors for cardio-
vascular events or death (1,2). Excess body weight, inde-
pendent of hypertension, is associated with several other
cardiovascular risk factors. For example, increased blood
levels of low-density lipoprotein cholesterol, low levels of
high-density lipoprotein cholesterol (3), increased left ven-
tricular muscle mass (4) and renal hyperfiltration (5). Be-
cause many of these findings are also associated with
hypertension, it could be anticipated that the obese hyper-
tensive patient would have an exaggerated susceptibility to
these abnormalities. Paradoxically, though, it has been
reported that lean hypertensive patients might have a worse
cardiovascular prognosis than obese hypertensive patients
(6,7). This apparent advantage to obese hypertensive pa-
tients appears to persist even when other risk factors are
taken into account (8). This has led to speculation that
obese hypertension and lean hypertension represent two
genetically distinct forms of hypertension (8), but no clear-
cut genetic differences have been established that can
explain the differences in clinical outcomes between the two
types of hypertension. It should also be recognized that
although obese hypertensive patients might have better
clinical outcomes than lean hypertensive patients, their
prognosis is still poorer than that of lean people with normal
blood pressures (6,8).
The main goal of the present study was to test the
hypothesis that differences in catecholamine and renin
values might discriminate between obese hypertension and
lean hypertension. In particular, we have examined whether
responses to standardized treadmill testing might reveal
properties of these two conditions that might further explain
the differences in their clinical outcomes. In addition, we
have performed the same observations in obese and lean
normotensive control subjects to determine which charac-
teristics can be attributed to hypertension and which to
obesity.
METHODS
A total of 197 volunteers participated in this study. Of
these, 121 were hypertensive and were classified into those
who were obese (body mass index [BMI] .30 kg/m2, n 5
55) and those who were lean (BMI ,25 kg/m2, n 5 66).
These two groups were matched for age and blood pressure.
There were 76 normotensive subjects; 21 were obese and 55
were lean (defined the same as for the hypertensive pa-
tients). The two normotensive groups were matched with
From the *State University of New York Downstate Medical Center, Brooklyn,
New York; and the †Veterans Affairs Medical Center, Long Beach, California. This
work was supported by Merit Review funding of the Department of Veterans Affairs.
Manuscript received May 18, 2000; revised manuscript received August 3, 2000,
accepted September 20, 2000.
Journal of the American College of Cardiology Vol. 37, No. 1, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01103-7
each other for age and blood pressure, and with their
respective hypertensive counterparts for age and BMI. The
hypertensive patients either had never been treated for
hypertension or had been free of treatment for at least six
months. They were identified by a hospital-sponsored
screening program. They were excluded from the study if
they had a history or any clinical findings indicative of
secondary hypertension. Diastolic blood pressures were in
the range 90 to 109 mm Hg. The blood pressures for
analysis in the study were based on an average of three
readings in each patient measured at 2-min intervals after
the patient had been comfortably seated for 5 min.
All subjects were carefully instructed in the collection of
a 24-h urine sample. Collections were regarded as adequate
if 24-h urinary creatinine measurements exceeded 10 mg/kg
body weight in women and 15 mg/kg in men. Blood
samples for insulin were drawn after an overnight fast.
Blood samples for measurement of plasma renin activity
were drawn from an indwelling venous port after at least 1 h
in the upright position. Blood samples for catecholamine
measurements were also drawn from an indwelling venous
port after the patient had been quietly recumbent for
30 min. In addition, samples for renin and catecholamines
were drawn from an indwelling venous port immediately
before treadmill exercise (with the patient standing ready on
the treadmill) and immediately on completion of the exer-
cise protocol. Urinary protein values were measured by
nephelometry. Plasma values of renin activity (9) and insulin
(10) were measured by radioimmunoassay techniques, and
plasma catecholamine concentrations were measured by a
radioenzyme method (11).
M-mode and two-dimensional echocardiographic studies
were performed from parasternal and apical windows. Stan-
dard views were obtained by using a commercially available,
phased-array, Doppler echocardiographic instrument (Gen-
eral Electric, Pass II or RT500). Standard M-mode echo-
cardiograms were recorded from the parasternal window on
strip chart paper at a speed of 50 mm/s. Left ventricular
mass was calculated in grams with the equation: left ven-
tricular mass 5 1.05 ([LVDD 1 PWT 1 VST]3 2
[LVDD]3), where VST 5 ventricular septal thickness;
LVDD 5 left ventricular diastolic dimension; and PWT 5
(left ventricular) posterior wall thickness (12). The ratio of
echocardiographically derived stroke volume to pulse pres-
sure (SV/PP ratio—the difference between systolic and
diastolic blood pressures measured in close proximity to the
echocardiographic procedure) was used as an index of total
body arterial compliance.
Each participant underwent a full treadmill test on two
separate occasions, according to a modified Balke-Ware
treadmill protocol (13). The data from the initial study were
used to individualize the protocol for each subject during the
definitive study treadmill session, which was performed
between 7 and 14 days after the initial session (14). After a
1-min warm-up at 2.0 mph/0% grade, the changes in speed
and grade were then computer-adjusted (based on each
subject’s exercise capacity during the baseline test) to yield a
test duration of 10 min. The walking speed was increased in
ramp fashion to a level between 2.7 and 4.2 mph, where it
remained constant; after that, the treadmill grade began
increasing at a rate ranging from 1.0% to 2.5%/min. For a
given subject, the overall ramp rate was constant during
changes in both speed and grade (14). Exercise was contin-
ued until volitional fatigue. A standard 12-lead electrocar-
diogram was obtained throughout the exercise test for safety
purposes and to exclude from analysis any patient who
revealed evidence of cardiac disease (there were no such
instances).
The principal analytic technique was to compare mea-
surements or responses to exercise among the four separate
groups (obese and lean hypertensive patients and obese and
lean normotensive subjects) using two-way analysis of vari-
ance. One factor was lean/obese, and the other was normo-
tension/hypertension. The interaction term between these
two factors was also tested (although, in fact, it did not
reach significance for any of the values measured in this
study). Regression analysis was done using the Pearson
method. Data are shown as the mean value 6 SEM. All
participants in the study signed an informed consent ap-
proved by the Institutional Review Board of the Long
Beach Veterans Affairs Medical Center.
RESULTS
Of the hypertensive patients in this study, 55 (8 women)
met the criteria for obese hypertension and 66 (9 women)
for lean hypertension. There were 21 obese normotensive
subjects (3 women) and 55 lean normotensive subjects (10
women). There were 41 non-Caucasian participants (32
Asian), again distributed evenly among the groups. Table 1
shows the values for age, BMI, blood pressure and heart rate
for each of the four study groups. There was no difference in
age among the groups, but by definition, BMI in both obese
groups was significantly greater than that in the lean groups.
However, there was no difference in BMI values between
the obese hypertensive patients and normotensive subjects
or between the lean hypertensive patients and normotensive
subjects. There were no differences in blood pressures
between either of the hypertensive groups or either of the
normotensive groups, although the differences between
hypertensive patients and normotensive subjects were sig-
nificant. Heart rate was similar across all groups. Values for
the four groups in blood concentrations of lipids, insulin,
catecholamines and renin activity are shown in Table 2.
Abbreviations and Acronyms
AER 5 albumin excretion rate
BMI 5 body mass index
LVMI 5 left ventricular mass index
PNE 5 plasma norepinephrine
SV/PP 5 stroke volume/pulse pressure ratio
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Lipid values in the obese hypertension group differed from
those in each of the other three groups, including the obese
normotensive group. Insulin concentrations were signifi-
cantly higher in the obese groups than in the lean groups.
There were no differences in catecholamine or renin values
between the four study groups.
Values for the cardiovascular measurements of left ven-
tricular mass index (LVMI) and total body compliance
(SV/PP ratio), as well as the renal measurements of creat-
inine clearance and urinary albumin excretion rate (AER),
are shown in Table 3. As compared with the lean normo-
tensive subjects, both the obese and lean hypertensive
patients, as well as the obese normotensive subjects, had
significantly higher LVMI values. Even the lean normoten-
sive group had a relatively high LVMI; this might reflect the
method used to calculate this value (12), or possibly a
tendency toward borderline changes in apparently normal
individuals who choose to attend a screening program. The
SV/PP ratio was significantly lower in the lean hypertensive
group than in any of the other groups. As compared with
the lean normotensive group, creatinine clearance was sig-
nificantly higher in both of the obese groups; AER was
higher in the obese hypertensive group than in any of the
other groups.
Correlations between the dependant variable LVMI and
the three principal neuroendocrine values—plasma renin
activity, plasma norepinephrine (PNE) and plasma epi-
nephrine—are shown in Figure 1. Each of these three
independent variables correlated significantly with LVMI in
the lean hypertensive patients, but these correlations were
not significant in the obese hypertensive patients. For the
dependent variable SV/PP ratio, there was a significant
relation (r 5 20.36, p 5 0.018) with norepinephrine in the
lean hypertensive patients. This correlation was not signif-
icant in the obese hypertensive patients (r 5 20.06);
however, in the obese but not the lean hypertensive patients
(r 5 20.11), the SV/PP ratio correlated significantly with
plasma insulin concentration (r 5 20.34, p 5 0.033).
The effects of standing (10 min in the upright posture) on
PNE concentrations were greater in the lean hypertensive
patients (104 6 17 pg/ml) than in the obese hypertensive
patients (47 6 11 pg/ml) or in the lean or obese (54 6 15
and 48 6 17 pg/ml) normotensive subjects (p 5 0.044 by
analysis of variance for obese vs. lean). The effects of
standing on PNE concentrations or plasma renin activity
were not different between any of the groups. Likewise,
there were no differences in changes in blood pressures or
heart rate between the groups on assuming the upright
posture. During treadmill exercise, there were no differences
between the four groups (obese and lean hypertensive
patients and obese and lean normotensive subjects) in either
maximal changes in systolic blood pressure (60 6 3, 61 6 3,
60 6 5 and 60 6 3 mm Hg, respectively) or maximal
changes in diastolic blood pressure (24 6 2, 25 6 2, 25 6
1 and 26 6 2 mm Hg, respectively). The changes during
treadmill exercise in plasma concentrations of epinephrine
and in plasma renin activity are shown in Figure 2 for the
two hypertensive groups and the two normotensive groups.
The changes in norepinephrine during treadmill testing
were not significantly different between the two groups.
However, the increases in both PNE concentration and
plasma renin activity were significantly greater in lean
participants as compared with obese ones.









Age (yr) 46 6 2 45 6 2 45 6 2 45 6 2
BMI (kg/m2) 32.5 6 0.3 24.3 6 0.2 31.8 6 0.6 23.9 6 0.2
Systolic BP (mm Hg) 145 6 2* 144 6 2* 126 6 2 124 6 2
Diastolic BP (mm Hg) 100 6 1* 98 6 1* 82 6 1 81 6 1
Heart rate (beats/min) 70 6 1 70 6 1 67 6 2 68 6 2
Data are presented as the mean value 6 SEM.
BMI 5 body mass index; BP 5 blood pressure; HTN hypertensive; Norm 5 normotensive.











Total cholesterol (mg/dl) 225 6 6 208 6 6 203 6 9 195 6 4 0.009*
LDL cholesterol (mg/dl) 153 6 4 135 6 6 131 6 5 123 6 7 0.048†, 0.037*
HDL cholesterol (mg/dl) 44 6 2 54 6 3 52 6 3 59 6 4 0.012†
Triglycerides (mg/dl) 182 6 18 133 6 10 120 6 12 117 6 12 0.037*
Insulin (mU/ml) 17.7 6 1.3 11.1 6 1.1 15.4 6 2.2 10.9 6 1.5 0.0004†
Norepinephrine (pg/ml) 252 6 20 259 6 21 231 6 18 224 6 17 NS
Epinephrine (pg/ml) 34 6 3 39 6 3 37 6 4 37 6 3 NS
Plasma renin activity (ngAI/ml per h) 2.2 6 0.2 2.3 6 0.2 2.2 6 0.4 2.1 6 0.2 NS
*Analysis of variance (ANOVA) for hypertensive patients vs. normotensive subjects. †ANOVA for lean vs. obese patients. There were no significant interactions between the
obesity and blood pressure factors with the two-way ANOVA. Data are presented as the mean value 6 SEM.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; NS 5 not significant; other abbreviations as in Table 1.
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DISCUSSION
This study has compared the characteristics of obese and
lean hypertension in two groups of patients matched for age
and blood pressure and, with additional control subjects, has
compared groups of normotensive subjects matched for age
and BMI with the respective hypertensive groups. The
study included relatively young patients with mild hyper-
tension who were identified primarily by a screening pro-
cess. For this reason, there was no overt clinical evidence of
cardiovascular or renal pathology in the participants, and the
findings were not confounded by current or recent antihy-
pertensive therapy. Reflecting the population served by our
institution, the participants in this study were predomi-
nantly white and male; in future studies, it would be
important to extend this work to a more diverse community.
Responses to exercise. The primary goal of this investiga-
tion was to determine whether obese and lean hypertensive
patients could be differentiated by their responses to a
standardized treadmill protocol. In fact, there was no
difference between the two hypertensive groups, or their
respective normotensive control groups, in their maximal
systolic or diastolic blood pressure changes during the
procedure. However, there were significantly greater in-
creases in both plasma epinephrine concentrations and
plasma renin activity in the lean hypertensive patients as
compared with the obese ones. The corresponding changes
in the normotensive groups were virtually identical to those
in the hypertensive patients, indicating that obesity—
regardless of whether or not hypertension is present—may
have an inhibitory effect on the neuroendocrine response to
physical stress. We also observed that the increase in PNE
concentrations on standing, possibly a reflection of acute
sympathetic activation, was greater in the lean hypertensive
patients than in the obese ones.
Cardiovascular and renal findings. The role of sympa-
thetic factors in hypertension in the obese individual is not
clear. In a large number of studies reporting measurements
of plasma or urinary norepinephrine levels at rest or during
unspecified activity, approximately equal numbers of studies
Figure 1. Correlation coefficients for the relations between left ventricular
mass index (LVMI) and plasma renin activity or plasma concentrations of
norepinephrine and epinephrine in obese and lean hypertensive patients.
The r values are significant by univariate analysis for each of the variables
in the lean patients; however, by multivariate analysis, only the plasma
renin activity and norepinephrine relations remain in the model.
Figure 2. Changes in plasma renin activity and in plasma norepinephrine
(PNE) concentrations during treadmill testing in obese and lean hyper-
tensive patients and normotensive volunteers. By two-way analysis of
variance, the differences between the obese and lean patients were signif-
icant, but not the differences between hypertensive patients and normo-
tensive subjects











LVMI (g/m2) 137 6 7 135 6 4 133 6 4 120 6 4 0.031*
SV/PP (ml/mm Hg) 2.17 6 0.12 1.90 6 0.08 2.26 6 0.24 2.21 6 0.13 0.042*
creatinine clearance
(ml/min)
121 6 5 115 6 4 127 6 9 104 6 4 0.005†
Urine sodium (mEq/day) 167 6 13 159 6 10 163 6 16 153 6 10 NS
AER (mg/day) 144 6 16 101 6 10 108 6 13 85 6 6 0.034†
*Analysis of variance (ANOVA) for hypertensive patients vs normotensive subjects. †ANOVA for lean versus obese patients. There were no significant interactions between the
obesity and blood pressure factors with the two-way ANOVA. Data are presented as the mean value 6 SEM.
AER 5 albumin excretion rate; LVMI 5 left ventricular mass index; SV/PP 5 stroke volume to pulse pressure ratio; other abbreviations as in Table 1.
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showed that catecholamine levels were higher in obese
hypertensive patients or were higher in lean hypertensive
patients, or were similar in each (15). This is consistent with
the findings in the present study, where rest plasma cate-
cholamine levels were similar in obese and lean hypertensive
patients. It has been suggested, though, by such techniques
as norepinephrine spillover (16) or microneurography (17),
that there might be increased sympathetic activity in obe-
sity; but, again, these findings may not be consistent (15).
Indeed, cardiac left ventricular muscle mass in the present
study correlated significantly with plasma concentrations of
norepinephrine and epinephrine, as well as with plasma
renin activity, in the lean hypertensive patients but not in
the obese ones. However, other investigators have previ-
ously shown that left ventricular mass in obese individuals
appears to be primarily related to increased body weight (4),
perhaps reflecting the known myocardial trophic effects of
the peptide hormone leptin, which is produced by adipose
tissue (18).
The SV/PP ratio, which is used as an index of total
arterial compliance (19), differed between the two hyper-
tensive groups. It was significantly lower, suggesting in-
creased arterial stiffness, in the lean hypertensive patients as
compared with the obese hypertensive patients or normo-
tensive control subjects. This finding may be of clinical
relevance, for SV/PP has been shown to be predictive of
physiologic changes in the vasculature (20) and recently was
found to have predictive value, even when adjusted for other
risk factors, for subsequent clinical cardiovascular events
(21). In the present study, this measure of arterial compli-
ance correlated inversely with plasma concentrations of
norepinephrine in the lean hypertensive group, but not in
any of the other groups. It is possible, therefore, that arterial
stiffening may be a characteristic of lean hypertension that
distinguishes it from obese hypertension.
There are differences in renal function between obese and
lean hypertensive patients. Obesity appears to increase renal
sodium reabsorption (22,23), very likely because of height-
ened renal sympathetic activity (24). This, in turn, could
help explain the increased plasma volume and cardiac output
found in obese individuals (25). This study has shown that
the glomerular filtration rate, as measured by creatinine
clearance, is significantly higher in both hypertensive and
normotensive obese individuals as compared with lean
normotensive control subjects. The lean hypertensive pa-
tients also exhibited an increase in glomerular filtration.
Similar findings have been reported previously (5). Like-
wise, we found an increase in the albumin excretion rate in
the obese hypertensive patients, probably reflecting their
high glomerular filtration rate. Another finding, also previ-
ously well demonstrated (3), was the clearly abnormal lipid
profile in the obese hypertensive patients. Obesity, per se,
may not fully explain these abnormalities, because as com-
pared with the obese normotensive group, the obese hyper-
tensive group had higher low density lipoprotein and lower
high density lipoprotein cholesterol concentrations. Thus,
the combination of obesity and hypertension in this partic-
ular group seems to have additive adverse effects on the lipid
profile.
Therapeutic implications. The hemodynamic data of
obese hypertension are characterized by increased stroke
volume but normal peripheral resistance, whereas in lean
hypertension, stroke volume is normal but peripheral resis-
tance in increased (26–28). A recently published report
based on a re-analysis of the Systolic Hypertension in the
Elderly Program (SHEP) has highlighted the prognostic
importance of these differing hemodynamic profiles (29).
Treatment with the diuretic chlorthalidone was most effec-
tive at reducing mortality in overweight hypertensive pa-
tients. Indeed, in hypertensive patients with BMI #24
kg/m2, normally considered a desirable weight, the risk of
adverse events rose sharply (29). The findings of the present
study that cardiovascular changes in lean hypertensive pa-
tients are at least partly mediated by activity of the renin-
angiotensin and sympathetic systems may help explain why
diuretic therapy, which stimulates these systems, is not fully
effective in preventing clinical end points in lean patients. It
would also be most interesting to test whether such agents
as angiotensin-converting enzyme inhibitors might be pref-
erentially effective in thin hypertensive patients.
Overall, these findings emphasize that obese hyperten-
sion and lean hypertension are two distinct conditions. As
established previously (26), obese patients with hyperten-
sion are characterized by abnormalities of insulin and lipid
metabolism and have evidence for left ventricular hypertro-
phy, renal hyperfiltration and albuminuria. Lean hyperten-
sive patients have similar findings, but they are more
dependent on the sympathetic and renin systems. Moreover,
in this study, there was an attenuated neuroendocrine
response to stress in the obese patients, which might also
help to explain why they appear to have a cardiovascular
prognostic advantage over lean patients (6–8,29).
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